Relmada Therapeutics (RLMD) Expected to Post Earnings on Thursday

Relmada Therapeutics (NASDAQ:RLMD) is projected to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Relmada Therapeutics (NASDAQ:RLMD) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.04). On average, analysts expect Relmada Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Relmada Therapeutics Trading Up 3.2%

Relmada Therapeutics stock opened at $5.47 on Wednesday. Relmada Therapeutics has a 12 month low of $0.55 and a 12 month high of $8.00. The company has a market capitalization of $573.75 million, a price-to-earnings ratio of -5.02 and a beta of 0.46. The business’s fifty day simple moving average is $6.17 and its two-hundred day simple moving average is $5.92.

Institutional Trading of Relmada Therapeutics

A number of institutional investors have recently made changes to their positions in RLMD. XTX Topco Ltd purchased a new position in shares of Relmada Therapeutics during the second quarter valued at approximately $28,000. Goldman Sachs Group Inc. bought a new stake in Relmada Therapeutics in the 1st quarter worth approximately $33,000. LMR Partners LLP purchased a new stake in Relmada Therapeutics during the 2nd quarter valued at $33,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Relmada Therapeutics during the 4th quarter valued at $64,000. Finally, Jane Street Group LLC bought a new position in shares of Relmada Therapeutics during the 2nd quarter valued at $69,000. Hedge funds and other institutional investors own 45.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. HC Wainwright began coverage on Relmada Therapeutics in a research report on Thursday, June 18th. They issued a “buy” rating and a $12.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Relmada Therapeutics in a research report on Thursday, June 18th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.